Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic
  • Search Hotels in Daly City

  • ROOMS:

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company’s Deep Learning Technology

Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced new data demonstrating that applying the company’s artificial intelligence (AI) algorithms to vectorcardiography (VCG) showed considerably improved performance in the detection of atrial flutter over single-lead electrocardiograms (ECGs) and similar performance to 12-lead ECGs, the standard for diagnosing atrial flutter. This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI. The data was presented by Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at The Mount Sinai Hospital, during the European Heart Rhythm Association (EHRA) conference in Berlin, Germany.

In the study, HeartBeam AI with VCG demonstrated a 28% improvement over single-lead ECG in the detection of atrial flutter cases (sensitivity of 91.0% for VCG vs. 71.2% for single-lead ECG) without sacrificing the ability to identify those individuals without atrial flutter (specificity of 98.7% for VCG vs. 96.9% for single-lead ECG). Additional details about the study can be found here.

Smartwatches have become increasingly popular for detecting and monitoring abnormalities in the timing or pattern of heartbeats but only offer a single-lead ECG, which greatly limits their ability to detect a broad range of cardiac irregularities. Atrial flutter is a common irregularity, or arrhythmia, that typically requires a healthcare professional to administer a 12-lead ECG in a medical setting which is not always practical or even possible at the time of a cardiac event.

HeartBeam’s core vectorelectrocardiography (3D VECG) technology captures the heart’s signals in three projections (X, Y, Z), similar to VCG, and synthesizes a 12-lead ECG. The technology is designed to be used in HeartBeam’s small, portable, patient-friendly devices that allow for remote cardiac monitoring. The Company’s first planned application of the 3D VECG platform technology is the HeartBeam AIMIGo™, a credit card-sized device for patient use at home or anywhere, which is currently under review with FDA.

“The study presented at the EHRA conference shows that HeartBeam AI combined with VCG delivers equivalent performance to a 12-lead ECG and greatly improves detection of atrial flutter over a single-lead ECG, underscoring the limitations of current wearable technologies. This presents an opportunity for a VCG-based algorithm that offers arrhythmia detection capabilities beyond what is available today and to fill gaps in healthcare inequality when obtaining a 12-lead ECG is challenging,” said Dr. Reddy.

The HeartBeam technology gathers far more data than a single-lead ECG. By leveraging AI to analyze these data-rich signals, HeartBeam believes it will be able to improve diagnostic accuracy and the technology has the potential to extract unique information that could go beyond today’s 12-lead ECGs as data of great diagnostic value is gathered from the same patients using the device over time. HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.

“The intent of our AI program is to leverage our novel VECG platform to unlock detection and prediction capabilities currently limited to healthcare facilities and make them readily accessible and available to the patient, and this new data is a clear example of what we can accomplish,” said Branislav Vajdic, PhD, CEO and Founder of HeartBeam. “As we continue to expand our artificial intelligence capabilities, we look forward to demonstrating how the combination of our data rich 3D VECG platform with HeartBeam AI has the potential to transform how cardiac health is managed in the future.”

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that is dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (VECG) technology collects 3D signals of the heart’s electrical activity and converts them into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining how cardiac health is managed in the future. For additional information, visit

Forward-Looking Statements

All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.